National Cancer Institute; Notice of Meeting, 90024-90025 [2024-26430]
Download as PDF
<![CDATA[
90024
Federal Register / Vol. 89, No. 220 / Thursday, November 14, 2024 / Notices
to licensing should be directed to
Andrew Burke, Ph.D., Senior
Technology Transfer Manager, NCI,
Technology Transfer Center, Email:
burkear@mail.nih.gov or Phone: 240–
276–5484.
SUPPLEMENTARY INFORMATION: Success in
immunotherapy is often attributable to
the reactivity of patient T-cells to
specific mutated peptide(s) found in the
patient’s tumor known as neoepitopes.
In the development of patient-specific
immunotherapies, there is no consistent
standard for prioritizing such
neoepitopes. Current models arrive at a
ranked list of potential candidates by
removing epitopes based on predetermined criteria which might lead to
the elimination of known reactive
neoepitopes. Identification,
prioritization and targeting of patient
neoepitopes are crucial for developing
effective, personalized treatments.
Ranking or prioritizing neoepitopes is
especially important when trying to
construct a cancer vaccine that will
elicit a therapeutically beneficial
immune response. Accordingly,
scientists at the NCI created a novel
approach to identify and prioritize
patient neoantigens. This model uses a
training dataset of known neoantigens
from patient screening and determines
features of importance to epitope
recognition using both reactive and nonreactive epitopes. The machine learning
algorithm scores epitopes for their
likelihood of reactivity and provides a
stable, reproducible method to prioritize
epitopes that can be used anywhere.
This Notice is in accordance with 35
U.S.C. 209 and 37 CFR part 404.
NIH Reference Number: E–022–2024–
0.
Potential Commercial Applications
• Oncology.
• Prioritization of neoantigens for the
development of effective personalized
therapies:
Æ Cancer vaccines.
Æ TIL and T-cell receptor therapies.
• Add-on to current color fundus
imaging modalities.
ddrumheller on DSK120RN23PROD with NOTICES1
Competitive Advantages
• Model is trained using a dataset of
verified neoantigens from patient tumor
data.
• Model is unbiased because it does
not use prior assumptions about what
features a neoepitope should have.
• Uses two models (MMP and NMER
model) as a more reproducible approach
than a single model.
• Particularly useful for prioritizing
epitopes for patients with large numbers
of mutations.
VerDate Sep<11>2014
20:16 Nov 13, 2024
Jkt 265001
Publication: A machine learning
model for ranking candidate HLA class
I neoantigens based on known
neoepitopes from multiple human
tumor types. (PMID: 34927080).
Product Type: Research Tool.
Development Stage: Prototype.
Therapeutic Area(s): Cancer.
Dated: November 8, 2024.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2024–26464 Filed 11–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer
Advisory Board (NCAB) and NCI Board
of Scientific Advisors (BSA).
This will be a hybrid meeting held inperson and virtually and will be open to
the public as indicated below.
Individuals who plan to attend inperson or view the virtual meeting and
need special assistance or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
can be accessed from the NIH Videocast
at the following link: https://
videocast.nih.gov/.
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended.
The intramural programs and projects
and the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the
intramural programs and projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Advisory Board.
Date: December 2, 2024.
Open: 6:00 p.m. to 9:00 p.m.
Agenda: National Cancer Advisory Board
Subcommittee Meetings.
Place: Gaithersburg Marriott
Washingtonian Center, Room—TBD, 9751
Washington Boulevard, Gaithersburg, MD
20878 (In Person Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room. 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Name of Committee: National Cancer
Advisory Board.
Date: December 3, 2024.
Closed: 8:00 a.m. to 8:45 a.m.
Agenda: Review of intramural program site
visit outcomes and the discussion of
confidential personnel issues.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Room
TE406 & 408, Rockville, MD 20850 (In Person
and Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room. 7W444,
Bethesda, MD 20892 240–276–6340, grayp@
mail.nih.gov.
Name of Committee: National Cancer
Advisory Board and NCI Board of Scientific
Advisors.
Date: December 3, 2024.
Open: 9:00 a.m. to 4:00 p.m.
Agenda: Joint meeting of the National
Cancer Advisory Board and NCI Board of
Scientific Advisors, NCI Director’s report and
presentations, NCI Board of Scientific
Advisors Concepts Review.
Place: National Cancer Institute—Shady
Grove, 9609 Medical Center Drive, Room
TE406 & 408, Rockville, MD 20850 (In Person
and Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room 7W444,
Bethesda, MD 20892 240–276–6340 grayp@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NCI-Shady Grove campus. All
visitors will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: NCAB: https://
deainfo.nci.nih.gov/advisory/ncab/
ncab.htm,BSA: https://deainfo.nci.nih.gov/
advisory/bsa/bsa.htm, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
E:\FR\FM\14NON1.SGM
14NON1
Federal Register / Vol. 89, No. 220 / Thursday, November 14, 2024 / Notices
Dated: November 7, 2024.
David W. Freeman,
Supervisory Program Analyst Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–26430 Filed 11–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel: Member
Conflict: Molecular Genetics and Evolution.
Date: December 9, 2024.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Linda Wagner Jurata,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health. 6701 Rockledge Drive, Bethesda, MD
20892, (301) 496–8032, linda.jurata@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel: Biomedical
Imaging and Cardiovascular and Surgical
Devices.
Date: December 10, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Krystyna H. Szymczyk,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 480–4198, szymczykk@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel PAR Panel:
Countermeasures Against Chemical Threats
Exploratory/Developmental and Full
Projects.
Date: December 10, 2024.
Time: 9:30 a.m. to 8:00 p.m.
VerDate Sep<11>2014
20:16 Nov 13, 2024
Jkt 265001
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jonathan K. Ivins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2190,
MSC 7850, Bethesda, MD 20892 (301) 594–
1245, ivinsj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel: Member
Conflict: Topics in HIV Comorbidities,
Coinfections and Associated Cancers.
Date: December 10, 2024.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Raul Rojas, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6185,
Bethesda, MD 20892, (301) 451–6319, rojasr@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel: PAR–24–
174: Fogarty Global Infectious Disease
Research Training Program.
Date: December 10, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Dayadevi Jirage, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4422,
Bethesda, MD 20892, (301) 867–5309,
jiragedb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel: Member
Conflict: Skin and Connective Tissue
Sciences.
Date: December 10, 2024.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Yi-Hsin Liu, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, Bethesda, MD 20892, (301) 435–1781,
liuyh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel: Member
Conflict: Adaptive and Innate Immunity
Special Emphasis Panel.
Date: December 10, 2024.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Susan Daum, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
90025
Health, 6701 Rockledge Drive, Room 3202,
Bethesda, MD 20892, 301–827–7233,
susan.boyle-vavra@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 8, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–26496 Filed 11–13–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Nursing Research;
Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Nursing Research.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Registration is not required to attend
this meeting. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
can be accessed from the NIH Videocast
at the following link: https://
videocast.nih.gov/.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The intramural programs
and projects as well as the grant
applications and/or contract proposals
and the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: The National
Advisory Council for Nursing Research
(NACNR).
Date: January 28, 2025.
Open: 9:00 a.m. to 3:00 p.m.
Agenda: Call to Order and Opening
Remarks, NINR Director’s Report, Discussion
of NINR Programs, Council Open Discussion.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Room 6C,
Bethesda, MD 20892 (Hybrid Meeting).
E:\FR\FM\14NON1.SGM
14NON1
]]>Agencies
[Federal Register Volume 89, Number 220 (Thursday, November 14, 2024)]
[Notices]
[Pages 90024-90025]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-26430]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Cancer
Advisory Board (NCAB) and NCI Board of Scientific Advisors (BSA).
This will be a hybrid meeting held in-person and virtually and will
be open to the public as indicated below. Individuals who plan to
attend in-person or view the virtual meeting and need special
assistance or other reasonable accommodations, should notify the
Contact Person listed below in advance of the meeting. The meeting can
be accessed from the NIH Videocast at the following link: https://videocast.nih.gov/.
A portion of the National Cancer Advisory Board meeting will be
closed to the public in accordance with the provisions set forth in
section 552b(c)(6), Title 5 U.S.C., as amended. The intramural programs
and projects and the discussions could disclose confidential trade
secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the
intramural programs and projects, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board.
Date: December 2, 2024.
Open: 6:00 p.m. to 9:00 p.m.
Agenda: National Cancer Advisory Board Subcommittee Meetings.
Place: Gaithersburg Marriott Washingtonian Center, Room--TBD,
9751 Washington Boulevard, Gaithersburg, MD 20878 (In Person
Meeting).
Contact Person: Paulette S. Gray, Ph.D., Director, Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, 7th Floor,
Room. 7W444, Bethesda, MD 20892, 240-276-6340, [email protected].
Name of Committee: National Cancer Advisory Board.
Date: December 3, 2024.
Closed: 8:00 a.m. to 8:45 a.m.
Agenda: Review of intramural program site visit outcomes and the
discussion of confidential personnel issues.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Room TE406 & 408, Rockville, MD 20850 (In Person and
Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D., Director, Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, 7th Floor,
Room. 7W444, Bethesda, MD 20892 240-276-6340, [email protected].
Name of Committee: National Cancer Advisory Board and NCI Board
of Scientific Advisors.
Date: December 3, 2024.
Open: 9:00 a.m. to 4:00 p.m.
Agenda: Joint meeting of the National Cancer Advisory Board and
NCI Board of Scientific Advisors, NCI Director's report and
presentations, NCI Board of Scientific Advisors Concepts Review.
Place: National Cancer Institute--Shady Grove, 9609 Medical
Center Drive, Room TE406 & 408, Rockville, MD 20850 (In Person and
Virtual Meeting).
Contact Person: Paulette S. Gray, Ph.D., Director, Division of
Extramural Activities, National Cancer Institute--Shady Grove,
National Institutes of Health, 9609 Medical Center Drive, 7th Floor,
Room 7W444, Bethesda, MD 20892 240-276-6340 [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NCI-Shady Grove campus. All
visitors will be asked to show one form of identification (for
example, a government-issued photo ID, driver's license, or
passport) and to state the purpose of their visit.
Information is also available on the Institute's/Center's home
page: NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm,BSA:
https://deainfo.nci.nih.gov/advisory/bsa/bsa.htm, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
[[Page 90025]]
Dated: November 7, 2024.
David W. Freeman,
Supervisory Program Analyst Office of Federal Advisory Committee
Policy.
[FR Doc. 2024-26430 Filed 11-13-24; 8:45 am]
BILLING CODE 4140-01-P
